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Abstract  
The prognostic factors and optimal therapy for invasive pulmonary aspergillosis (IPA) after 
kidney transplantation (KT) remain poorly studied. We included in this multinational 
retrospective study 112 recipients diagnosed with probable (75.0% of cases) or proven (25.0%) 
IPA between 2000 and 2013. The median interval from transplantation to diagnosis was 230 
days. Cough, fever and expectoration were the most common symptoms at presentation. 
Bilateral pulmonary involvement was observed in 63.6% of cases. Positivity rates for the 
galactomannan assay in serum and bronchoalveolar lavage samples were 61.3% and 57.1%. 
Aspergillus fumigatus was the most commonly identified species. Six- and 12-weeks survival 
rates were 68.8% and 60.7%, and 22.1% of survivors experienced graft loss. Occurrence of IPA 
within the first 6 months (hazard ratio [HR]: 2.29; P-value = 0.027) and bilateral involvement at 
diagnosis (HR: 3.00; P-value = 0.017) were independent predictors for 6-week all-cause 
mortality, whereas the initial use of a voriconazole-based regimen showed a protective effect 
(HR: 0.34; P-value = 0.007). The administration of antifungal combination therapy had no 
apparent impact on outcome. In conclusion, IPA entails a dismal prognosis among KT 
recipients. Maintaining a low clinical suspicion threshold is key to achieve a prompt diagnosis 
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Introduction 
Invasive pulmonary aspergillosis (IPA) constitutes a devastating complication that affects 
severely immunosuppressed patients. Subjects with hematological malignancies represent the 
subpopulation with the highest incidence and the worst prognosis among those prone to 
developing IPA (1). In addition, this life-threatening infection is also described in other groups of 
patients, as those with solid organ malignancies (1), chronic pulmonary diseases (2), admission 
to intensive care units (3) or solid organ transplantation (SOT) (4,5). Among this latter group, 
the highest incidence of IPA is described in lung transplant recipients, followed by heart and 
liver transplant recipients (4,6). The risk of IPA after kidney transplantation (KT) is relatively 
lower compared to those observed for other SOT populations, with incidence rates below 0.5% 
in most studies (6-8). Nevertheless, KT represents by far the most common transplant 
procedure. For example, more than 77,000 KT were performed worldwide in 2012 in 
comparison to 23,000 liver, 5,900 heart and 4,300 lung transplants (9). Therefore, KT recipients 
suffer from the highest burden of IPA events in absolute terms (8,10-12). 
Despite this reality, our knowledge about the clinical presentation of IPA in KT recipients and its 
impact on patient and graft survival is scarce and mostly based on small case series (13) or 
studies including different SOT populations (11,14-17) or invasive fungal diseases (IFD) due to 
both molds and yeasts (18-20). Only one single-center case-control study (which included 41 
cases of IPA) has specifically analyzed the determinants of outcome among KT recipients, 
although no details on clinical or radiological features were provided (21). 
The generalization of use of anti-mold prophylaxis has markedly reduced the incidence of IFD 
among patients with hematological malignancies or hematopoietic stem cells transplantation 
(HSCT). This approach has been also extended to specific high-risk subgroups of liver and 
heart transplant recipients (4,22), although so far no formal recommendation has been made 
regarding the need for antifungal prophylaxis in KT recipients or the optimal targeted therapy 
once the diagnosis of post-transplant IPA has been established. Such a lack of evidence raises 
further concern in view of the high mortality rates (ranging from 39% to 61%) observed in 
previous studies (16,17,20,21). 
Thus, additional information is urgently needed to better define the clinical picture of IPA in KT 
recipients and to gain insight into its determinants of outcome and best therapeutic approaches, 
with the ultimate aim of improving the dismal prognosis associated to this opportunistic 
infection. The present study was designed to collect detailed data derived from the joint effort of 
a multinational group in order to override the intrinsic limitation imposed by the limited number 















This article is protected by copyright. All rights reserved 
Patients and Methods  
Study design 
We performed a multinational retrospective cohort study in 29 hospitals located in Europe 
(Spain, Switzerland, Belgium, Portugal, France and United Kingdom) and the Americas (United 
States, Brazil, Mexico and Argentina). The Swiss Transplant Cohort Study contributed with the 
collective experience from 6 transplant centers in Switzerland (23,24). Participating centers 
were invited to include all the cases of proven or probable IPA diagnosed in KT recipients 
between January 1, 2000 and December 31, 2013. By using an standardized data collection 
form, anonymized information on demographic and baseline characteristics; post-transplant 
events; clinical, microbiological and radiological features of IPA; therapeutic approaches; and 
patient and graft outcome were collected for each case by local investigators and entered in a 
protected electronic database. 
The primary outcome was all-cause mortality at 6 weeks from diagnosis. This outcome was 
chosen in line with recent clinical trials (25) due to its objective nature and close relatedness 
with IPA-attributable mortality (26). Secondary outcomes included all-cause mortality at 12 
weeks from diagnosis and graft loss among those patients who survived beyond that point. The 
retrospective design of the study and the lack of homogeneity in terms of follow-up schedules 
after the initiation of antifungal therapy (i.e., timing of follow-up thoracic computed tomography 
[CT] scan) precluded us from selecting clinical and radiological response as study outcome. 
This study was developed with the institutional support of the Spanish Network Research of 
Infectious Diseases (REIPI) and the Group for the Study of Infection in Transplant Recipients 
(GESITRA) of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). 
The study protocol was approved by the Ethic Committee of the coordinating center as well as 
by the local Ethics Committees of the different participating centers, as required. The study was 
performed in accordance to the Helsinki Declaration and the Declaration of Istanbul on Organ 
Trafficking and Transplant Tourism. 
Study definitions 
Post-transplant IPA was defined according to the criteria proposed in 2008 by the European 
Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative 
Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group 
(EORTC/MSG) Consensus Group (27). We only included IPA cases that fulfilled modified 
EORTC/MSG definitions for probable or proven diagnosis categories. Cases were deemed as 
“proven IPA” when the diagnosis was established by the visualization of molds in a lung biopsy 
(or autopsy) with the simultaneous recovery of Aspergillus spp. in culture from lung biopsy, 
sputum, bronchoalveolar lavage (BAL) or bronchial brush samples. Cases were categorized as 
“probable IPA” on the basis of the simultaneous presence of at least one host factor plus a 
radiological criterion plus a mycological criterion. The host factor was assumed to be the receipt 
of KT under chronic immunosuppressive therapy. The modified radiological criteria included not 
only the demonstration of dense, well-circumscribed lesions (with or without halo sign or 
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to previous clinical experiences suggesting that IPA in SOT recipients may be accompanied by 
lung infiltrates (i.e., peribronchial consolidation or tree-in-bud pattern) that differ from the typical 
signs observed in hematological patients (6,28). The microbiological criteria included the 
recovery of Aspergillus spp. in culture from sputum, BAL or bronchial brush samples and/or a 
positive galactomannan (GM) assay (≥0.5 optical densities [OD] in plasma or serum specimens 
and ≥1.0 in BAL specimens). Imaging response in the follow -up CT scan was defined as 
complete (more than 90% radiographic improvement compared with baseline), partial (more 
than 50% radiographic improvement compared with baseline), stable (no change from baseline 
or less than 50% radiologic improvement) or failure (progression of disease). Mortality was 
assessed by review of medical chart records, institutional databases, regional or national 
transplant registries and their corresponding mortality information systems, as appropriate for 
each participating center. Mortality was considered to be “IPA-attributable” when the patient 
died with microbiological, histological or clinical evidence of active IPA and other potential 
causes of death could be excluded by the attending physician or the local site investigator. All 
cases were independently reviewed by an infectious disease specialist at the coordinating 
center. According to the interval between transplantation and diagnosis, cases of IPA were 
categorized as “early” (<180 days) or “late” forms (≥180 days). Given the long time frame of this 
study, an era effect was taken into account by dividing the cohort according to the date of 
diagnosis of IPA (2000-2006 and 2007-2013). 
“Initial antifungal therapy” was that provided within the first two weeks of administration of 
systemic antifungal drugs with activity against Aspergillus for the episode of IPA. For the 
purpose of the present study, “active antifungal drugs” comprised the following classes: the 
different formulations of amphotericin B (amphotericin B deoxycholate [AmB-D], amphotericin B 
lipid complex [AmB-LC] or liposomal amphotericin B [L-AmB]), anti-mold triazoles (itraconazole 
[either as oral solution or capsules], voriconazole or posaconazole), and echinocandins 
(caspofungin, anidulafungin or micafungin). “Antifungal combination therapy” was defined as the 
concomitant use as initial therapy of two or more of these drugs for ≥72 hours within the first two 
weeks of therapy. A patient that was given two or more different drugs initiated at least two 
weeks apart was considered to have received monotherapy (categorized according to the first 
drug used). “Sequential therapy” was defined as the use of one systemic antifungal followed by 
its discontinuation and replacement with another drug (an overlap period of 48 hours or less 
was allowed), also within the first two weeks. For the purposes of multivariate analyses, patients 
receiving sequential therapy were classified according to the last drug used (providing it was 
administered for ≥50% of the overall length of therapy). 
“Cytomegalovirus (CMV) disease” included viral syndrome and probable or definitive end-organ 
disease, as previously defined (29). The diagnosis of pneumonia included hospital-acquired, 
health-care associated and ventilator-associated forms. Only laboratory-confirmed cases of 
influenza were analyzed. “Delayed graft function” denoted the requirement for dialysis within the 
first two weeks after transplantation. “Acute graft rejection” was diagnosed by histological 
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glomerular filtration rate (eGFR) was assessed by the 4-variable Modification of Diet in Renal 
Disease (4-MDRD) equation (31). “Graft loss” was defined as the need for permanent return to 
dialysis and/or retransplantation. 
Statistical analysis 
Quantitative data were shown as the mean ± standard deviation (SD) or the median with 
interquartile ranges (IQR). Qualitative variables were expressed as absolute and relative 
frequencies. Categorical variables were compared using the χ2
A potential center effect on the primary study outcome was accounted for through the Cochran's 
and Mantel-Haenszel statistics by grouping participating centers according to two criteria: the 
center contributing the largest number of cases versus all other centers pooled, and those 
contributing less than 5 cases versus those contributing ≥5 cases. 
 test, whereas Student’s T test or 
U Mann-Whitney test were applied for continuous variables. Survival curves were estimated by 
the Kaplan-Meier method, and differences between groups were compared with the log-rank 
test. Univariate and multivariate Cox regression models were used to identify factors predicting 
all-cause mortality at 6 and 12 weeks, as well as graft loss among survivors. For the latter 
outcome, the week 12 after diagnosis of IPA was used as reference time point for survival 
analysis. Those variables found to be significant (P-value <0.05) at the univariate level were 
included into the multivariate models in a backward stepwise fashion. To estimate survival 
curves the date of diagnosis of IPA was set at the calendar day in which the first clinical sample 
yielding Aspergillus spp. or the first positive GM assay was obtained. Associations are 
expressed as hazards ratios (HRs) with 95% confidence intervals (CIs). Sensitivity analyses 
were performed using a bootstrap approach to adjust the estimated HR for overfitting. Bootstrap 
validation estimates how good the performance of the prediction model obtained from the 
development set would be on a hypothetical set of new patients (32). To this aim, 200 bootstrap 
samples of equal size were generated from the study population by sampling with replacement. 
To partially overcome the limitation posed by the non-randomized design of our study, and as a 
preliminary approach, we calculated the propensity for receiving antifungal combination therapy 
(versus monotherapy or sequential therapy) given the patient’s baseline characteristics and the 
clinical and radiological features of IPA at presentation. This score was estimated using a 
backward stepwise logistic regression model including variables with P-values <0.1 in the 
univariate analysis. In addition, and to increase the precision of the estimated exposure effect 
without increasing bias, we also adjusted the model for selected variables that were unrelated to 
the exposure (i.e., antifungal regimen), but significantly associated to the study outcome (6-
week mortality). The fit of this model was assessed by means of the Hosmer-Lemeshow test 
and the area under the receiving operator characteristics curve (auROC). We then performed a 
1:1 nearest neighbor matching on the propensity score with replacement and a caliper width of 
0.25 to select two subgroups of patients (receiving combination therapy or other regimens) that 
were comparable in their pre-treatment characteristics (33). 
All the significance tests were two-tailed. Statistical analysis was performed using SPSS version 
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Prism version 6.0 (GraphPad Software Inc., La Jolla, CA), and the propensity score matching 















This article is protected by copyright. All rights reserved 
Results  
Study cohort 
We included 112 KT recipients from 33 different institutions (mean number of cases per center: 
3.9 [range: 1-20]) (Table S1  in Supplementary Material). According to the EORTC/MSG criteria 
there were 28 cases (25.0%) of proven IPA, whereas the remaining 84 (75.0%) were classified 
as probable (of which 21 [25.0%] received this diagnostic category on the basis of the 
abovementioned modified radiological criteria). Three-quarter of the cases occurred between 
2007 and 2013. The median interval between transplantation and diagnosis was 230 days (IQR: 
95.5-1117.8), with 51 (45.5%) and 61 cases (54.5%) occurring before and after the month 6 
(early and late forms, respectively) (Figure 1 ). Two cases (1.8%) were diagnosed at autopsy. 
Six- and 12-week follow-up were achieved in 76 and 66 patients (which accounted for 98.7% 
[76/77] and 97.0% [66/68] of patients surviving at each of these points, respectively). 
Clinical presentation 
The baseline and transplant-related characteristics according to the timing of diagnosis are 
shown in Table 1 . As compared to those with late IPA, recipients suffering from early forms had 
older donors, were receiving higher doses of corticosteroids and were more likely to be under 
tacrolimus-containing regimens at diagnosis, had been more frequently diagnosed with 
pneumonia, CMV disease, bloodstream infection and acute graft rejection during the three 
preceding months, and had been more commonly admitted into the intensive care unit (ICU) 
within that period. 
Table 2  details the clinical, radiological and microbiological features of IPA cases. Most of the 
patients presented with cough, fever and expectoration, and had multilobar involvement in the 
form of nodules in the CT scan, whereas extrapulmonary involvement was uncommon. Of note, 
20 patients (18.0%) had no fever, expectoration or pleuritic chest pain at the time of diagnosis. 
We found no significant differences in clinical or radiological findings between early and late 
forms. Regarding the diagnostic procedures, patients with early IPA were more likely to undergo 
BAL in comparison to late cases. The positivity rates for the GM assay in serum and BAL 
samples were 61.3% (38/62) and 57.1% (12/21), respectively (60.0% [30/50] and 50.0% [9/18] 
when the analysis was restricted exclusively to probable cases). As expected, A. fumigatus was 
the most common species among the 99 episodes (88.4%) in which speciation was obtained. 
Therapeutic approaches and outcome 
One hundred and nine patients (97.3%) received some type of antifungal therapy with activity 
against Aspergillus. Therapy was initiated within the first 24 or 48 hours from diagnosis in most 
of the patients (67.0% [73/109] and 77.1% [84/109], respectively). The median duration of 
therapy was 42.5 days (IQR: 13-108-8). Voriconazole was the agent most commonly used in 
monotherapy (43.1% [47/109]), followed by L-AmB (9.2% [10/109]). Patients treated with L-AmB 
in monotherapy had poorer graft function at diagnosis of IPA than those receiving other 
regimens (baseline eGFR: 32.1 ± 20.0 versus 45.4 ± 33.7 mL/min/1.72 m2; P-value = 0.037). 
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likely to be initially given L-AmB in monotherapy (22.7% [5/22] versus 5.7% [5/87]; P-value = 
0.027). The median dose of L-AmB was 5.0 mg/Kg/day (range: 3-10). As shown in Table 3 , 22 
patients (20.1%) received antifungal combination therapy for a median period of 14 days, with 
voriconazole plus echinocandin (45.5% [10/22]) being the most common regimen. Sequential 
therapy was used in 16 patients (14.7%). Overall, there were no significant differences in 
therapeutic approaches according to the timing of diagnosis, except for the higher use of L-AmB 
in early IPA cases compared to late cases (16.3% [8/49] versus 3.3% [2/60], respectively; P-
value = 0.019). Daily corticosteroid dose was reduced from baseline by ≥50% in 28.0% (21/109) 
of patients within the first month following diagnosis, particularly in cases of early IPA (40.0% 
[12/30] versus 20.0% [9/45]; P-value = 0.059). 
Following the diagnosis of IPA, 22 patients (19.6%) required ICU admission for a median of 
10.5 days (IQR: 3-23.5). A follow-up CT scan was performed in 64 patients (57.1%) after a 
median interval of 90 days (IQR: 46-197), and showed complete response in 35.9% of cases 
(23/64), partial response in 46.9% (30/64), stable disease in 9.4% (6/64) and failure in 7.8% 
(5/64). Six- and 12-weeks survival rates were 68.8% (95% CI: 59.7-76.6) and 60.7% (95% CI: 
51.5-69.3), respectively. Most of the deaths at week 12 (75.0% [33/44]) were considered 
attributable to IPA, including 7 out of 9 cases that underwent autopsy. The median interval from 
diagnosis to death was significantly shorter for IPA-attributable mortality than for other causes 
(8.5 versus 38.5 days, respectively; P-value = 0.006). The 68 patients that survived beyond 
week 12 were additionally follow-up for a median of 638.5 days (IQR: 119-1474.5), and graft 
loss was reported in 15 of them (22.1%). 
Predictive factors for mortality 
Table 4  shows the comparison between survivors and non-survivors at 6 weeks from diagnosis 
of IPA in terms of clinical characteristics and therapeutic approaches. By univariate analysis, it 
was found that survivors were more commonly diagnosed during the most recent study period 
(2007-2013) and treated with a voriconazole-based regimen. In contrast, non-survivors were 
more likely to have undergone invasive mechanical ventilation prior to diagnosis, to have early 
forms of IPA and bilateral pulmonary involvement, to receive combination therapy, and to 
require ICU admission and acute renal replacement therapy. The GM indexes in serum and 
BAL samples were also significantly higher compared to survivors. 
The Cox regression model revealed that early IPA (HR: 2.29; 95% CI: 1.10-4.79; P-value = 
0.027) and bilateral involvement (HR: 3.00; 95% CI: 1.22-7.39; P-value = 0.017) were 
independently associated with a higher mortality, whereas the use of a voriconazole-based 
regimen as initial therapy exerted a protective effect (HR: 0.34; 95% CI: 0.15-0.74; P-value = 
0.007). Although the administration of combination therapy appears to increase the risk of 
mortality at the univariate level, such an effect did not remain in the multivariate model. The 
HRs and corresponding 95% CIs of the bootstrap resampling procedure based on 200 samples 
were similar to those obtained in the original model (data not shown). Survival rates at 6 weeks 
were significantly lower in patients with early IPA (56.0% versus 79.0%; log-rank P-value = 
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84.0%; log-rank P-value = 0.002) (Figure 2 ). The Cochran's and Mantel-Haenszel statistics did 
not find any evidence of center effect on these associations. In addition, their direction and 
magnitude remained essentially unchanged when analyses were restricted to proven cases, 
although lacking statistical significance due the low number of patients analyzed (data not 
shown). 
As expected, patients that were given antifungal combination therapy significantly differed in 
terms of baseline characteristics and markers of disease severity in comparison to those treated 
with monotherapy or sequential regimens, including higher rates of pre-transplant dialysis, 
previous transplantation, chronic hepatitis C virus (HCV) infection and dyspnea and hemoptysis 
at presentation, higher number of lesions in the CT scan at diagnosis, and higher absolute 
neutrophil count at day 7, among others (Table S2 ). On the basis of these variables we 
estimated the propensity score for receiving antifungal combination therapy compared to 
monotherapy or sequential therapy. In addition, the timing of diagnosis (early versus late IPA) 
and the requirement for ICU admission at presentation were also entered into the model. The 
resulting score showed a good goodness-of-fit (Hosmer-Lemeshow test P-value = 0.794; 
auROC: 0.816; 95% CI: 0.698-0.935). There was an acceptable overlap between propensity 
scores for patients who were given one or other regimen, thus providing sufficient power for 
propensity adjustment in the survival analyses (Figure S1 ). Following assignment of propensity 
scores, each patient receiving combination therapy was matched to a single patient receiving 
monotherapy or sequential therapy who has the most similar estimated propensity score (i.e., 
the smallest distance). The lack of impact of combination therapy on the primary outcome was 
confirmed in this propensity-matched subanalysis (HR: 1.37; 95% CI: 0.43-4.31; P-value = 
0.596). 
The comparison between survivors and non-survivors at 12 weeks from diagnosis of IPA are 
shown in Table S3 . Early occurrence of IPA (HR: 2.11; 95% CI: 1.01-4.09; P-value = 0.028), 
bilateral pulmonary involvement (HR: 2.49; 95% CI: 0.99-6.32; P-value = 0.053), and the 
requirement for ICU admission (HR: 2.24; 95% CI: 1.12-4.48; P-value = 0.023) and acute renal 
replacement therapy (HR: 2.00; 95% CI: 0.99-4.05; P-value = 0.054) were predictors of all-
cause mortality at 12 weeks. Of note, the administration of combination therapy exerted a 
negative impact on this outcome (HR: 2.11; 95% CI: 1.04-4.29; P-value = 0.039), although such 
effect disappeared in the propensity-matched cohort (HR: 2.32; 95% CI: 0.80-6.69; P-value = 
0.120). The presence of a positive HCV serostatus was identified as a risk factor at univariate 
but not multivariate analysis. Again, the bootstrap estimates of the multivariate HRs and 95% 
CIs were similar to those obtained from the original sample (data not shown). 
Since the demonstration of bilateral lung involvement was identified to exert a negative impact 
on outcome, we further explored the factors associated to this condition at diagnosis. Patients 
with bilateral or unilateral infection did not significantly differ in terms of pre-transplant 
comorbidities, prior occurrence of acute graft rejection or CMV disease, or leukocyte or 
lymphocyte counts at diagnosis. On the other hand, dyspnea at presentation, higher number of 
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eGFR) were associated to bilateral involvement. In the multivariate logistic regression analysis 
the presence of dyspnea, number of nodules and graft function remained as independent 
predictor factors (Table S4). 
Predictive factors for graft loss 
Finally, we assessed the risk factors for the occurrence of graft loss among those patients that 
remained alive at 12 weeks from diagnosis of IPA (Table S5 ). The use of acute renal 
replacement therapy (HR: 16.89; 95% CI: 4.59 - 60.60; P-value <0.001) and the requirement for 
ICU admission, either within the 3 months prior to (HR: 4.24; 95% CI: 1.28 - 14.05; P-value = 
0.018) or at the time of diagnosis (HR: 3.68; 95% CI: 1.04 - 12.99; P-value = 0.043) emerged as 
independent predictors, although it should be noted that the number of events analyzed was low 
(n = 15). The administration of any amphotericin B-containing regimen was identified as a risk 
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Discussion  
To our knowledge, the present study represents the largest cohort assessing the clinical 
characteristics and outcome of IPA among KT recipients and the first one to include detailed 
data on microbiological and radiological features. Some relevant clinical and prognostic 
information may be derived from our series. Firstly, IPA was found to be a devastating disease 
in the setting of KT, as 20% of the patients had to be admitted to the ICU following diagnosis, 
31% had died at 6 weeks (43% if IPA occurred within the first 180 days after transplantation), 
and as much as 20% of survivors suffered from graft lost and required permanent return to 
dialysis or retransplantation. 
It should be highlighted that almost half of the cases of IPA were diagnosed within the first 6 
months after transplantation. Similar results have been communicated from previous smaller 
cohorts (21). Therefore, a low threshold for suspicion of this complication must be maintained 
throughout such period, particularly in view that the time interval to the onset of infection also 
exerted a relevant prognostic effect. Early cases of IPA had increased risk of death at 6 and 12 
weeks, even after adjusting for a large range of potential confounders. The lack of obvious 
differences between early and late cases in variables reflecting disease severity (such as the 
number of nodules in CT scan or the requirement for ICU admission) or appropriateness of 
therapeutic approach suggests that the worse prognosis observed for the former would be 
primarily driven by host’s factors. Indeed, subgroup comparisons suggest that patients 
diagnosed with IPA during the first 180 days had a greater immunosuppression (i.e., higher 
daily corticosteroid dose, previous occurrence of CMV disease or acute graft rejection) and 
poorer status (prior ICU admission) compared to those with later infection. 
From a clinical perspective, it is noteworthy that about one-fifth of the patients presented with no 
typical symptoms of respiratory tract infection (fever, expectoration or pleuritic chest pain), and 
that a non-specific manifestation, such as cough, was the most commonly observed complain. 
With regards to the findings of the CT scan, the presence of cavitation or halo sign —classically 
deemed as specific signs of IPA, particularly in the hematological patient (34)— was reported in 
only one-third and one-fourth of the cases, respectively. In contrast, well-circumscribe nodules 
constituted the most common radiological sign (about 70% of cases), in line with previous 
studies (35). We found that bilateral pulmonary involvement acted as an independent predictor 
for all-cause mortality. A similar association has been reported in cancer patients (36). It seems 
plausible that the demonstration of bilateral infection may represent a surrogate marker for 
delayed diagnosis and advanced disease, a hypothesis further supported by the fact that we 
found no apparent differences in the net state of immunosuppression between patients with 
unilateral or bilateral involvement. 
Our experience confirms that the more invasive is the diagnostic procedure, the greater is the 
possibility of achieving a microbiological confirmation to support the suspicion of IPA. Indeed, 
Aspergillus spp. was isolated in 18.2%, 31.8%, 58.5% and 85.0% of sputum, bronchial brush, 
BAL and lung biopsy samples, respectively. On the other hand, the GM assay was positive in 
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design of our study did not allow us to assess the diagnostic performance of this biomarker. A 
previous meta-analysis reported a pooled sensitivity in SOT recipients sensibly lower (41%) 
(37). Heylen et al. observed in their single-center experience that the serum GM assay was 
positive in one-third of KT recipients (21), whereas a recent study obtained high sensitivity but 
low specificity values among liver transplant recipients (38). Interestingly, the GM indexes in 
both serum and BAL samples were significantly higher in non-survivors at 6 weeks compared to 
survivors, although we could not demonstrate the impact of this variable in the multivariate Cox 
model likely due to the limited number of patients in which the assay was performed. In line with 
this finding, Heylen et al. also reported that the height of the GM index (>2 ODs) acted as a risk 
factor for mortality in their experience (21). In view of this, we propose that the GM assay should 
be ordered in KT recipients with suspected post-transplant IPA not only on the grounds of its 
diagnostic value, but also due to its prognostic significance. 
In relation to the therapeutic approaches, voriconazole monotherapy was administered as first-
line treatment in more than 40% of the patients included in our multinational series, and its use 
was independently associated with a better outcome at 6 weeks. All-cause mortality was lower 
among cases diagnosed during the most recent study era (2007-2013), probably reflecting the 
increasing use of voriconazole (approved in 2002 (39)) over the recent years as well as overall 
improvements in post-transplant management. A similar trend has been observed for patients 
with heart (40) and liver (41) transplantation and hematological malignancies (36). Likewise, the 
positive impact of voriconazole-based regimens on mortality was also found in other high-risk 
populations, including HSCT recipients (16), patients with hematological malignancies (36), 
overall SOT recipients (16) and liver transplant recipients (41). Voriconazole acts as a potent 
inhibitor of cytochrome P450 isoform CYP2C19, which poses an increased potential for 
clinically relevant interactions with certain immunosuppressive drugs (42). This threat must be 
carefully taken in consideration whenever prescribing this antifungal agent in SOT recipients. 
On the other hand, we found no significant association at the multivariate level between the use 
of voriconazole and 12-week mortality. Whereas it has been suggested that mortality at 6 weeks 
from diagnosis acts as a good surrogate for IPA-attributable mortality (26), later outcomes may 
be influenced to a greater extent by concurrent factors such as the loss of graft function or the 
severity of respiratory failure, even outweighing the protective role of antifungal therapy. In 
support of this, the requirement for ICU admission and renal replacement therapy following 
diagnosis emerged as independent risk factors for 12-week mortality. In that sense, 
voriconazole-based therapy remained significant in the multivariate analysis when both 
variables were removed from the Cox model (data not shown). Moreover, we cannot rule out 
that our study lacked statistical power to demonstrate differences in 12-week mortality 
according to the antifungal regimen. Interestingly, positive HCV serostatus exerted a negative 
impact on this outcome at the univariate level. Various studies have reported poorer patient and 
graft survival among HCV-positive KT recipients (43-45), and some of these series identified 
infectious complications as one of the leading causes of mortality (46), suggesting a reciprocal 
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The initial use of antifungal combination therapy —mostly voriconazole plus echinocandin— 
was found to be related to poorer outcomes at the univariate level. However, the demonstration 
of imbalances in baseline and clinical characteristics suggests that this finding was likely subject 
to confounding by indication bias due to the observational design of our study, as further 
suggested by the lack of association observed in the propensity-matched cohort. Nevertheless, 
this subanalysis should be regarded as merely exploratory due to the low number of patients 
that were given combination regimens. The efficacy of the combination of voriconazole and an 
echinocandin as primary therapy for IPA remains controversial, with some retrospective studies 
suggesting a beneficial impact in SOT recipients compared to L-AmB monotherapy (47). A 
recent trial failed to demonstrate a clear benefit in patients with hematological malignancies or 
HSCT (25). 
In contrast to other SOT populations, a distinctive issue concerning the clinical management of 
KT recipients that develop severe opportunistic infections lies on the possibility of performing a 
more intensive reduction of immunosuppression, even by assuming the risk of graft rejection 
and graft loss. Indeed, the overall amount of immunosuppression at the time of diagnosis of IPA 
was tapered in 80% of the cases analyzed. It is likely that such as high rate precluded us from 
demonstrating the potential role of this approach in terms of patient outcome. 
A point of key interest in the setting of KT is the impact of post-transplant IPA on graft function 
and subsequent mortality. We observed that one-third of patients required acute renal 
replacement therapy at the time of diagnosis, and this factor was independently associated to 
all-cause mortality at 12 weeks. Renal failure is a well-described risk factor for poor outcome in 
HSCT recipients, patients with hematological o solid organ malignancies, and SOT recipients 
with IFD (5,16,36). Furthermore, more than 20% of survivors beyond week 12 developed graft 
loss, a complication that was more frequent among those requiring prior ICU admission and 
acute renal replacement therapy, as previously described for other SOT recipients (41). 
Although not achieving statistical significance in the multivariate model, we observed that the 
use of amphotericin B increased the risk of graft loss, thus emphasizing the role of voriconazole 
as first-line therapy not only on the grounds of better recipient survival, but also long-term graft 
function.  
Certain limitations to our study should be noted, mostly derived from its retrospective design. 
Some clinical data could not be retrieved for all cases (i.e., follow-up imaging). As previously 
mentioned, the administration of antifungal combination therapy was not random but based on 
physician’s criteria, and therefore particularly susceptible to confounding bias that cannot be 
completely removed through propensity score analysis. Moreover, these results should be 
interpreted with particular caution due to the reduced sample of the propensity-matched cohort. 
The prolonged inclusion period and the large number of participating centers, albeit 
strengthening the generalizability of our findings, entail some heterogeneity in terms of post-
transplant and critical care practices. However, we have attempted to take into account this “era 
effect” when assessing determinants of outcome. Finally, and despite our study being the 
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events may limit the stability of the multivariate analysis, since it has been demonstrated that 
the results of Cox models suffers from increasing bias and variability, unreliable confidence 
interval coverage, and problems with model convergence as the ratio of events to predictor 
variables declines below 10 (48). 
In summary, clinicians in charge of KT recipients must keep in mind the possibility of IPA in 
patients presenting with non-specific respiratory symptoms (such as cough), fever and nodular 
lung lesions, especially during the first months after transplantation. An aggressive diagnostic 
approach —which should includes GM testing in serum and BAL samples— and the prompt 
initiation of voriconazole-based therapy may be life-saving in this setting. Future studies are 
needed to better delineate the role of tapering immunosuppression in an attempt to improve the 
dismal prognosis of this opportunist infection without threatening the survival of the renal graft. 
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Figure legends  
Figure 1. Temporal distribution of cases of invasive pulmonary aspergillosis occurring within the 
first 3 years after transplantation according to post-transplant month of diagnosis (light gray 
columns: early forms [<180 days after transplantation]; dark grey columns: late forms [≥180 
days]). 
Figure 2.  Kaplan-Meier survival curves at week 6 after diagnosis of IPA according to: a) timing 
of diagnosis (log-rank P-value = 0.022) and b) type of initial antifungal regimen (log-rank P-
value = 0.002). IPA, invasive pulmonary aspergillosis. 
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Table S3: Uni- and multivariate analyses of risk factors predicting all-cause mortality at 12 
weeks. 
Table S4:  Uni- and multivariate logistic regression analyses of factors associated with bilateral 
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Tables 
Table 1. Demographics, pre-transplant and donor-related characteristics and post-transplant 
events in kidney transplant recipients with early (<180 days) and late IPA (≥180 days). 
Variable  
Overall  
(n = 112) 
Early IPA  
(n = 51) 
Late IPA  
(n = 61) 
P-valuea 
Age at transplantation, years [mean ± SD] 55.8 ± 14.9 57.3 ± 15.6 54.6 ± 14.3 0.340 
Gender (male) [n (%)] 70 (62.5) 37 (72.5) 33 (54.1) 0.045 
Pre-transplant conditions [n (%)]     
Diabetes mellitus 30 (26.8) 12 (24.0) 18 (29.5) 0.516 
COPD 19 (17.0) 8 (16.3) 11 (18.3) 0.784 
Pre-transplant corticosteroid therapy [n (%)] 12 (10.7) 6 (12.8) 6 (10.3) 0.698 
BMI at transplantation, Kg/m2 [mean ± SD] 25.1 ± 4.7 b 25.9 ± 5.7 24.4 ± 3.6 0.163 
Previous kidney transplantation [n (%)] 15 (13.4) 8 (15.7) 7 (11.5) 0.515 
Underlying end-stage renal disease [n (%)]     
Glomerulonephritis 26 (23.2) 11 (21.6) 15 (24.6) 0.706 
Diabetic nephropathy 20 (17.9) 8 (15.7) 12 (19.7) 0.583 
Policystosis 18 (16.1) 9 (17.6) 9 (14.8) 0.678 
Nephroangiosclerosis 10 (8.9) 5 (9.8) 5 (8.2) 0.766 
Chronic interstitial nephropathy 7 (6.3) 4 (7.8) 3 (4.9) 0.700 
Congenital nephropathy 4 (3.6) 1 (2.0) 3 (4.9) 0.624 
Unknown 12 (10.7) 5 (9.8) 7 (11.5) 0.776 
Other 15 (13.4) 8 (15.7) 7 (11.5) 0.515 
Pre-transplant serostatus [n (%)]  c    
HCV 11 (10.0) 5 (10.0) 6 (10.0) 1.000 
HBV surface antigen (HBsAg) 3 (2.7) 1 (2.0) 2 (3.3) 1.000 
CMV 86 (78.2) 41 (83.7) 45 (73.8) 0.211 
Pre-transplant dialysis [n (%)] 105 (93.8) 50 (98.0) 55 (90.2) 0.124 
Dialysis vintage, months [median (IQR)] 25 (15.5 - 47) 30 (17 - 57.8) 23 (15 - 41) 0.141 
Age of donor, years [mean ± SD] 52.5 ± 15.6 56.5 ± 14.0 49.0 ± 16.2 0.020 
Living donor [n (%)] 17 (15.5) c 5 (10.0) 12 (20.3) 0.138 
Prior antifungal prophylaxis [n (%)] 2 (4.3) 2 (9.5) 0 (0.0) 0.194 
Prior colonization with Aspergillus [n (%)] 5 (4.5) 1 (2.0) 4 (6.6) 0.374 
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T-cell depleting agents (ATG or OKT-3)  29 (26.4) 13 (26.5) 16 (26.2) 0.972 
Anti-CD25 monoclonal antibodies 47 (42.7) 24 (49.0) 23 (37.7) 0.235 
None 36 (32.7) 13 (26.5) 23 (37.7) 0.214 
Maintenance immunosuppression at 
diagnosis including [n (%)]
 
d 
   
Corticosteroids 101 (90.9) 47 (94.0) 54 (90.0) 0.507 
Daily dose, mg [median (IQR)] 10 (5 - 20) e 17.5 (10 - 21.3) 6 (5 - 10) <0.001 
Tacrolimus 63 (56.8) 35 (70.0) 28 (45.9) 0.011 
Cyclosporine 32 (28.8) 10 (20.0) 22 (36.1) 0.063 
MMF / MPA 80 (72.1) 36 (72.0) 44 (72.1) 0.988 
Azathioprine 7 (6.3) 2 (4.0) 5 (8.2) 0.455 
mTOR inhibitor 13 (11.7) 3 (6.0) 10 (16.4) 0.090 
Post-transplant events in the three months 
prior to diagnosis [n (%)] 
    
Pneumonia 23 (20.5) 15 (29.4) 8 (13.1) 0.033 
Laboratory-confirmed influenza 4 (3.6) 1 (2.0) 3 (4.9) 0.624 
CMV disease 16 (14.3) 11 (21.6) 5 (8.2) 0.044 
Bloodstream infection 18 (16.1) 14 (27.5) 4 (6.6) 0.003 
ICU admission at any time for ≥48 hours  15 (13.4) 13 (25.5) 2 (3.3) 0.001 
Invasive mechanical ventilation 9 (8.0) 7 (13.7) 2 (3.3) 0.077 
De novo malignancy 4 (3.6) 1 (2.0) 3 (4.9) 0.624 
Acute graft rejection 46 (41.1) 32 (62.7) 14 (23.0) <0.001 
ATG: antithymocyte globulin; BMI: body mass index; CMV: cytomegalovirus; COPD: chronic obstructive pulmonary 
disease; HBV: hepatitis B virus; HCV: hepatitis B virus; ICU: intensive care unit; IPA: invasive pulmonary aspergillosis; 
IQR: interquartile range; MMF / MPA: mofetil mycophenolate / mycophenolate acid; mTOR: mammalian target of 
rapamycin; SD: standard deviation. 
a P-values refer to comparison between early and late cases of IPA. Significant values are indicated in bold characters. 
b Data available for 78 patients. 
c Data available for 110 patients. 
d Data available for 111 patients. 
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Table 2. Clinical, radiological and microbiological features of IPA cases. 
Variable  
Overall  
(n = 112) 
Early IPA  
(n = 51) 
Late IPA 
(n = 61) 
P-valuea 
Age at diagnosis, years [mean ± SD] 58.3 ± 14.1 57.5 ± 15.6 58.9 ± 12.8 0.597 
EORTC/MSG category [n (%)]    0.584 
Proven diagnosis 28 (25.0) 14 (27.5) 14 (23.0)  
Probable diagnosis 84 (75.0) 37 (72.5) 47 (77.0)  
Symptoms at presentation [n (%)]  b    
Cough 83 (75.5) 39 (79.6) 44 (72.1) 0.366 
Fever 70 (63.1) 32 (64.0) 38 (62.3) 0.853 
Expectoration 63 (57.3) 28 (57.1) 35 (57.4) 0.980 
Pleuritic pain 42 (37.8) 20 (40.0) 22 (36.1) 0.671 
Dyspnea 25 (22.5) 10 (20.0) 15 (24.6) 0.565 
Hemoptysis 6 (5.4) 2 (4.0) 4 (6.6) 0.688 
Septic shock 3 (2.7) 0 (0.0) 3 (4.9) 0.251 
Extrapulmonary involvement [n (%)] 10 (8.9) c 5 (9.8) 5 (8.2) 0.766 
Findings on thoracic CT scan [n (%)]     
Number of lesions [median (IQR)] 2 (1 - 4) 2 (1 - 5) 2 (1 - 4) 0.970 
Maximum diameter, cm [median (IQR)] 2.3 (1.5 - 5.0) d 3.0 (2.0 - 4.5) 2.0 (1.4 - 5.8) 0.630 
Nodules 74 (69.8) 32 (69.6) 42 (70.0) 0.961 
Cavitation 32 (29.9) e 12 (25.5) 20 (33.3) 0.382 
Halo sign 26 (24.3) e 10 (21.3) 16 (26.7) 0.519 
Pleural effusion 44 (41.1) e 23 (48.9) 21 (35.0) 0.146 
Multilobar involvement 83 (76.9) 38 (79.2) 45 (75.0) 0.610 
Bilateral pulmonary involvement 68 (62.9) e 30 (63.8) 38 (63.3) 0.958 
Diagnostic procedures [n (%)]  e    
Sputum culture 33 (30.6) 17 (34.7) 16 (27.1) 0.395 
Positive identification 6 / 33 (18.2) 3 / 17 (17.6) 3 / 16 (18.8) 1.000 
Bronchial brush 22 (20.4) 9 (18.4) 13 (22.0) 0.638 
Positive identification 7 / 22 (31.8) 4 / 9 (44.4) 3 / 13 (23.1) 0.376 
BAL 53 (49.1) 30 (61.2) 23 (39.0) 0.021 
Positive identification 31 / 53 (58.5) 19 / 30 (63.3) 12 / 23 (52.2) 0.414 
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Positive identification 17 / 20 (85.0) 7 / 7 (100.0) 10 / 13 (76.9) 0.521 
Detection of GM in serum sample 62 (55.4) 26 (51.0) 36 (59.0) 0.394 
Positive (index ≥0.5 ODs) 38 / 62 (61.3) 15 / 26 (57.7) 23 / 36 (63.9) 0.621 
Positive (index ≥0.5 ODs) in probable 
cases 
30 / 50 (60.0) 11 / 19 (57.9) 19 / 31 (61.3) 0.812 
Detection of GM in BAL sample 21 (18.8) 8 (15.7) 13 (21.3) 0.448 
Positive (index ≥1.0 ODs) 12 / 21 (57.1) 5 / 8 (62.5) 7 / 13 (53.8) 1.000 
Positive (index ≥1.0 ODs) in probable 
cases 
9 / 18 (50.0) 3 / 6 (50.0) 6 / 12 (50.0) 1.000 
Isolated species [n (%)]  f   0.862 
Aspergillus fumigatus 78 (78.8) 36 (78.3) 42 (79.2)  
Aspergillus flavus  6 (6.1) 3 (6.5) 3 (5.7)  
Aspergillus niger 6 (6.1) 2 (4.3) 4 (7.5)  
Other 9 (9.1) g 5 (10.9) 4 (7.5)  
BAL: bronchoalveolar lavage; CT: computed tomography; EORTC/MSG: European Organization for Research and 
Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious 
Diseases Mycoses Study Group; GM: galactomannan; ICU: intensive care unit; IPA: invasive pulmonary aspergillosis; 
IQR: interquartile range; OD: optical density; SD: standard deviation. 
a P-values refer to comparison between early and late cases of IPA. 
b Data available for 111 patients. 
c Included involvement of central nervous system (3 cases), sinus (3 cases), skin (3 cases), liver (2 cases) and 
endocardium (one case). 
d Data available for 59 patients. 
e Data available for 108 patients. 
f Percentages calculated on the 99 cases (72 probable IPA and 27 proven) with Aspergillus speciation. 
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Table 3. Therapeutic approaches in patients that received any antifungal treatment (n = 109). 
Variable  N (%) 
Initial antifungal therapy  a 
Monotherapy 71 (65.1) 
Amphotericin B  
L-AmB 10 (9.2) 
AmB-D 5 (4.6) 
AmB-LC 1 (0.9) 
AmB-D plus AmB-LC 1 (0.9) 
Triazoles  
Voriconazole 47 (43.1) 
Itraconazole 3 (2.8) 
Echinocandins  
Caspofungin 2 (1.8) 
Anidulafungin 2 (1.8) 
Combination therapy 22 (20.1) b 
Voriconazole plus echinocandin 10 (9.2) 
Amphotericin B plus echinocandin 5 (4.6) 
Amphotericin B plus triazole 4 (3.7) 
Voriconazole plus echinocandin plus amphotericin B 3 (2.8) 
Sequential therapy 16 (14.7) c 
Amphotericin B followed by triazole 6 (5.5) 
Echinocandin followed by triazole 6 (5.5) 
Voriconazole followed by amphotericin B 2 (1.8) 
Amphotericin B followed by echinocandin 1 (0.9) 
Voriconazole followed by echinocandin 1 (0.9) 
Adjuvant therapy  
G-CSF 7 (6.4) 
Surgery 6 (5.5) 
Reduction in overall immunosuppression 80 (80.0) d 
Reduction by ≥50% in daily corticosteroid dose 21 (28.0) e 
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AmB-D: amphotericin B deoxycholate; AmB-LC: amphotericin B lipid complex; ICU: 
intensive care unit; IPA: invasive pulmonary aspergillosis; G-CSF: granulocyte-colony 
stimulating factor; IQR: interquartile range; L-AmB: liposomal amphotericin B; SD: 
standard deviation. 
a Refers to that administered during the first two weeks of therapy. 
b Refers to the concomitant administration for ≥72 hours of two or more active 
antifungal drugs within the first two weeks of therapy. 
c Refers to the consecutive administration of two or more active antifungal drugs 
within the first two weeks of therapy (an overlap period of less than 72 hours was 
allowed). 
d Within the first month after diagnosis of IPA. Data available for 100 patients. 
e Within the first month after diagnosis of IPA. Data available for 75 patients. 
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Table 4. Uni- and multivariate analyses of risk factors predicting all-cause mortality at 6 weeks from the diagnosis of IPA. 
Variable  
Survivors 
(n = 77) 
Non-survivors 




Univariate   Multivariate  
HR 95% CI P-value HR 95% CI P-value 
Age at diagnosis, years [mean ± SD] 58.6 ± 13.7 57.6 ± 15.1 0.720         
Male gender [n (%)] 49 (63.6) 21 (60.0) 0.713         
Diagnosis in 2007-2013 compared to 2000-
2006 [n (%)] 
62 (80.5) 22 (62.9) 0.045  0.50 0.25 - 0.99 0.048  - - - 
Pre-transplant diabetes mellitus [n (%)] 21 (27.6) 9 (25.7) 0.833         
Pre-transplant COPD [n (%)] 12 (16.2) 7 (20.0) 0.627         
Positive HCV serostatus 6 (7.9) 5 (14.7) 0.310         
Previous kidney transplantation [n (%)] 10 (13.0) 5 (14.3) 1.000         
Living donor [n (%)] 14 (18.4) 3 (9.1) 0.217         
Prior CMV disease [n (%)] 9 (11.7) b 7 (20.0) 0.244         




6 (17.1) 0.550         
Prior invasive mechanical ventilation [n (%)] 3 (3.9) b 6 (17.1) 0.026  2.79 1.15 - 6.75 0.023  - - - 
Prior acute graft rejection [n (%)] 28 (36.4) b 18 (51.4) 0.133         
Proven EORTC/MSG category [n (%)] 23 (29.9) 5 (14.3) 0.077         
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compared to late (≥180 days) [n (%)] 
Fever at presentation [n (%)] 44 (57.9) c 26 (74.3) 0.096         
Cough at presentation [n (%)] 58 (77.3) c 25 (71.4) 0.503         
Dyspnea at presentation [n (%)] 17 (22.4) c 8 (22.9) 0.954         
Extrapulmonary involvement [n (%)] 9 (11.7) 1 (2.9) 0.168         
Number of lesions [median (IQR)] 2 (1 - 4) 3 (1 - 4.8) 0.678         
Halo sign [n (%)] 21 (27.3) d 5 (16.7) 0.251         
Cavitation [n (%)] 23 (29.9) d 9 (30.0) 0.989         
Plural effusion [n (%)] 28 (36.4) d 16 (53.3) 0.109         
Multilobar involvement [n (%)] 56 (72.7) d 27 (87.1) 0.109         
Bilateral pulmonary involvement [n (%)] 43 (56.6) 25 (80.6) 0.019  2.64 1.08 - 6.44 0.033  3.00 1.22 - 7.39 0.017 
Serum GM index (ODs) [median (IQR)] 0.5 (0 - 1) e 1.1 (0.5 - 3.4) 0.024         
BAL GM index (ODs) [median (IQR)] 1 (0 - 3.1) f 6.5 (1.9 - 7.8) 0.014         
Initial antifungal therapy [n (%)]  g           
Amphotericin B-based regimen 13 (16.9) 6 (18.8) 0.815         
Voriconazole-based regimen 47 (61.0) 9 (28.1) 0.002  0.32 0.15 - 0.68 0.003  0.34 0.15 - 0.74 0.007 
Echinocandin-based regimen 2 (2.6) 4 (12.5) 0.060         
Combination regimen 10 (13.0) 12 (37.5) 0.004  2.60 1.27 - 5.34 0.009  - - - 
Interval from diagnosis to initiation of 
treatment <48 hours [n (%)] 
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Surgery [n (%)] 6 (7.8) g 0 (0.0) 0.177         




2 (22.2) 1.000         
Requirement for ICU admission [n (%)] 11 (14.3) g 11 (31.4) 0.017  2.06 1.01 - 4.20 0.048  - - - 
Requirement for acute renal replacement 
therapy at diagnosis of IPA [n (%)]
17 (22.1) 
g,i 
17 (53.1) 0.001  2.47 1.27 - 4.81 0.008  - - - 
BAL: bronchoalveolar lavage; CI: confidence interval; CMV: cytomegalovirus; COPD: chronic obstructive pulmonary disease; EORTC/MSG: European Organization for Research and 
Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group; GM: galactomannan; HCV: 
hepatitis C virus; HR: hazard ratio; ICU: intensive care unit; IPA: invasive pulmonary aspergillosis; IQR: interquartile range; OD: optical density; SD: standard deviation. 
a Significant P-values at the univariate level are indicated in bold characters. Unless otherwise specified, these variables were entered into the Cox regression model. 
b Within the three months prior to diagnosis of IPA. 
c Data available for 111 patients. 
d Data available for 108 patients. 
e Data available for 45 patients. This variable was not included into the model due to the low number of patients in which the assay was tested. 
f Data available for 17 patients. This variable was not included into the model due to the low number of patients in which the assay was tested. 
g Percentages calculated on the 109 patients that received any antifungal treatment. 
h Within the first month after diagnosis of IPA. Data available for 75 patients. 
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